Atrial Fibrillation Surgery Market Size, COVID-19 Impact Analysis, Regional Outlook, Application Growth Potential, Competitive Market Growth & Forecast, 2021 – 2027
Report ID: GMI1831
Atrial Fibrillation Surgery Market expansion during 2021-2027 will be largely influenced by the increasing burden of various cardiovascular and chronic health issues. Globally, diabetes, hypertension, obesity, and unhealthy lifestyles choices such as excessive alcohol consumption are among the leading causes of atrial fibrillation (AF). It is one of the most prevalent forms of chronic arrythmia among older patients. Thus, a large elderly population base will continue to open promising opportunities for the market.
In the U.S. alone, the occurrence of AF is projected to reach more than 12 million by 2030, as per the CDC. The growing burden of the condition along with numerous other health problems and complications will bolster industry outlook. Also known as atrial fibrillation ablation, AF surgery is a procedure used for treating arrythmias that begin in the upper chambers of the heart.
Considering the product landscape, the industry is bifurcated into surgical ablation and catheter ablation. The catheter ablation market is likely gain traction through 2027 led by increasing adoption of the technology. Recently in June 2021, the American Heart Association (AHA) had highlighted that the catheter ablation could result in better management and positive outcomes in atrial fibrillation patients with heart failure and reduced ejection fraction (HFrEF). These factors along with the various benefits of catheter ablation indicate that it will witness robust acceptance in the coming years.
Atrial fibrillation surgery market share across hospitals will grow substantially by the end of 2027, mainly due to availability of sophisticated technologies for disease treatment. Availability of skilled surgeons and staff and robust healthcare infrastructure are among the other advantages of treatment at hospitals. Collaboration of hospitals with insurers will positively impact the industry dynamics.
Geographically, Europe will continue to hold a notable share of the market over 2021-2027 impelled by the high occurrence rate of AFA and increasing awareness regarding the various options available for its treatment. Increased number of people with diabetes, obesity, heart disease, and hypertension will also contribute significantly towards the regional revenue. Healthcare providers are focusing on providing favorable insurance policies for patients. All these factors combined with the presence of major healthcare device makers augment Europe market trends.
Boston Scientific, Biotronik, Medtronic, St. Jude Medical, Biosense Webster (Johnson & Johnson), Articure, Cardiofocus, and Cardima are among the prominent names in the atrial fibrillation surgery market at present. Mergers, acquisitions, and partnerships are some of the key strategies used by market players to gain a competitive advantage.
For instance, in September 2020, Boston Scientific had acquired a 27% stake in its longstanding partner Farapulse. In June 2021, Boston Scientific announced plans to take over the remainder of the company for USD 295 million. With this deal, the company aims to accelerate work towards FDA clearance for its ablation technologies for AF and other cardiac arrythmias.
The atrial fibrillation surgery market is observing constant innovations as industry players prioritize research and development. Citing a recent instance, in June 2021, Medtronic had received the U.S. FDA clearance for its cryoablation catheter for atrial fibrillation treatment. The device can go as low as -75°C, blocking abnormal electrical signals that cause rapid of irregular heartbeats.
How has COVID-19 influenced atrial fibrillation surgery market dynamics?
The coronavirus pandemic has created positive opportunities for atrial fibrillation industry as arrythmia and acute cardiac injury are among the most prevalent complications in COVID-19 patients, especially those who had to received care in the ICU. Since, patients with cardiovascular diseases are at a greater risk of multiple organ failure, expenditure on treatment procedures has surged.
The pandemic has, however, led to reduced number of AF ablation procedures, with majority of providers postponing surgery dates and recommending patients to stay at home since they are more vulnerable to COVID-19 virus infection. Many providers have also switched to telemedicine to provide remote consulting and monitoring of patients to reduce the risk of exposure to COVID-19. The improving COVID-19 situation in the near future should strengthen market outlook over 2021-2027.
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability